DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
The generic ingredient in EMPAVELI is pegcetacoplan. Additional details are available on the pegcetacoplan profile page.
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 215014
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||SOLUTION;SUBCUTANEOUS||Strength||1080MG/20ML (54MG/ML)|
|Approval Date:||May 14, 2021||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||May 14, 2026|
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
|Regulatory Exclusivity Expiration:||May 14, 2028|
|Regulatory Exclusivity Use:||TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)|
|Patent:||⤷ Try it Free||Patent Expiration:||Nov 15, 2033||Product Flag?||Substance Flag?||Y||Delist Request?|
Complete Access Available with Subscription